Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

2018 Xofigo (radium-223; Bayer) Drug Analysis: A Radioisotope that Kills Tumor Cells with Highly Localized Short-Range Alpha Irradiation - ResearchAndMarkets.com

Research and Markets
Posted on: 15 Feb 18

The "Drug Analysis: Xofigo" drug pipelines has been added to ResearchAndMarkets.com's offering.

Xofigo (radium-223; Bayer) is a radioisotope that kills tumor cells with highly localized short-range alpha irradiation. The drug acts as a calcium mimic and is taken up in the areas of increased bone metabolism, which are associated with bone metastases. Xofigo has a long enough half-life of 11.43 days from synthesis for manufacturing and distribution, but the serum half-life of Xofigo is short, with around 0.5% remaining in the blood after 24 hours.

Product Profiles

List of Figures

Figure 1: Xofigo for prostate cancer - SWOT analysis

Figure 2: Drug assessment summary of Xofigo for prostate cancer

Figure 3: Drug assessment summary of Xofigo for prostate cancer

Figure 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017-26

List of Tables

Table 1: Xofigo drug profile

Table 2: Xofigo Phase III data in prostate cancer

Table 3: Xofigo Phase III trials in prostate cancer

Table 4: Xofigo sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017-26

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/25wr34/2018_xofigo?w=4

View source version on businesswire.com: http://www.businesswire.com/news/home/20180215005579/en/

Business Wire
www.businesswire.com

Last updated on: 15/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.